Related Articles
Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Top Research in Axial Spondyloarthritis Presented at ACR Convergence 2022
PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…
Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.